logo

Nektar Therapeutics (NKTR)



Trade NKTR now with
  Date
  Headline
12/17/2019 9:06:13 AM Nektar Therapeutics Appoints Myriam Curet As An Independent Director To Its Board
12/9/2019 10:07:26 AM Nektar Therapeutics Announces Presentation Of New Preclinical Data For Its IL-15 Agonist, NKTR-255
12/3/2019 9:01:40 AM Nektar Appoints John Northcott As Chief Commercial Officer
11/7/2019 9:16:03 AM William Blair Is Increasing Nektar Therapeutics (NKTR) FY21 Estimate To -3.22 From -4.41
11/7/2019 9:15:45 AM William Blair Is Raising Nektar Therapeutics (NKTR) FY20 Estimate To -3.00 From -3.92
11/7/2019 9:14:16 AM William Blair Is Increasing Nektar Therapeutics (NKTR) FY19 Estimate To -2.59 From -3.18
11/7/2019 8:52:44 AM William Blair Reiterates Nektar Therapeutics (NKTR) At Outperform
11/6/2019 4:06:59 PM Nektar Therapeutics Q3 Loss/share $0.56, Same As Last Year
10/16/2019 9:02:15 AM Nektar Therapeutics Announces Initiation Of First-in-Human Phase 1 Clinical Study Of NKTR-255
10/7/2019 9:03:08 AM Nektar Initiates 2 Studies Of Novel T Regulatory Cell Stimulator NKTR-358 In Patients With Psoriasis, Atopic Dermatitis
10/1/2019 8:03:34 AM Nektar Therapeutics Promotes Gil Labrucherie To COO In Addition To His Role As CFO
9/26/2019 7:02:17 AM Nektar Therapeutics Reports Presentation Of New Clinical Data For Bempegaldesleukin With Nivolumab
8/8/2019 4:25:20 PM Nektar Therapeutics Q2 Loss/share $0.63 Vs. Profit $5.33 Year Ago
8/1/2019 7:24:38 AM Nektar, Bristol-Myers Announce FDA Breakthrough Therapy Designation For NKTR-214 In Combination With Opdivo